Arch Therapeutics Inc (ARTH)

[Polyphemus]

Basic question...is AC5 a viable competitor in a crowded, price sensitive market in which distribution is important? After 40 months, talking about unique technology has not translated into either competitive product advantages or clinical outcomes improvement vs. current practice. The revenue numbers do the REAL talking. AC5 is an apparent loser as a wound dressing.

Part of the issue may be that TN lacks experience & ARTH funds are misspent on exec & director comp, but AC5 wound dressing has shown NO traction. Quo vadis?